Interestingly, the T-type calcium channel blocker mibefradil, which was previously shown to restore the sensitivity of resistant melanoma cells to BRAF and MEK inhibitors [21], was also able to reduce vem-induced HER3 and STAT3 activation. Here, MAP2K7 is linked to melanoma.